Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies by R.J. Harris et al.
Prognostic importance of anaemia in HIV-1 infected patients 
starting antiretroviral therapy: collaborative analysis of 
prospective cohort studies in industrialized countries
Ross J Harris1, Jonathan AC Sterne1, Sophie Abgrall2,3, François Dabis4, Peter Reiss5, 
Michael Saag6, Andrew N Phillips7, Geneviève Chêne4, John M Gill8, Amy C Justice9, 
Jürgen Rockstroh10, Caroline A Sabin7, Amanda Mocroft7, Heiner C Bucher11, Robert S 
Hogg12, Antonella D’Arminio Monforte13, Margaret May1, Matthias Egger14, and The 
Antiretroviral Therapy (ART) Cohort Collaboration*
1Department of Social Medicine, University of Bristol, UK 2INSERM U720, Paris, Université Pierre 
et Marie Curie-Paris 6, Paris, France 3Department of Infectious and Tropical Diseases, Avicenne 
Hospital, Bobigny, France 4INSERM U330, Université Victor Segalen, Bordeaux, France 5HIV 
Monitoring Foundation and National AIDS Therapy Evaluation Center, Academic Medical Centre 
of the University of Amsterdam, Amsterdam, Netherlands 6Division of Infectious Diseases, 
Department of Medicine, School of Medicine, University of Alabama, Birmingham, AL 
7Department of Primary Care and Population Sciences, Royal Free and University College 
Medical School, London, UK 8Division of Infectious Diseases, University of Calgary, Calgary, 
Canada 9Yale University School of Medicine, New Haven, Connecticut; the †VA Connecticut 
Healthcare System, West Haven, Connecticut; 10Medizinische Universitätsklinik – 
Immunologische Ambulanz, Bonn, Germany 11Basel Institute for Clinical Epidemiology, University 
Hospital Basel, Switzerland 12Division of Epidemiology and Population Health, BC Centre for 
Excellence in HIV/AIDS, Vancouver, Canada 13Ospedale “L. Sacco,” Milan, Italy 14Institute of 
Social and Preventive Medicine, University of Bern, Bern, Switzerland
Correspondence to: Professor Matthias Egger, Institute of Social & Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 
11, CH-3012 Bern, Switzerland. egger@ispm.unibe.ch, Tel: +41 31 631 3501, Fax: +41 31 631 3520.
*See end of paper for writing committee and members of collaboration
The Antiretroviral Therapy (ART) Cohort Collaboration
Steering committee
Geneviève Chêne, Dominique Costagliola, François Dabis, Antonella D’Arminio Monforte, Frank de Wolf, Matthias Egger, Gerd 
Fatkenheuer, John Gill, Robert Hogg, Amy Justice, Bruno Ledergerber, Jens Lundgren, Margaret May, Andrew Phillips, Peter Reiss, 
Caroline Sabin, Jonathan Sterne, Schlomo Staszewski, Ian Weller
Collaborating cohorts
French Hospital Database on HIV (FHDH); Italian Cohort of Antiretroviral-Naive Patients (ICONA); Swiss HIV Cohort Study 
(SHCS); AIDS Therapy Evaluation project Netherlands (ATHENA); The Multicenter Study Group on EuroSIDA; Collaborations in 
HIV Outcomes Research US (CHORUS); Frankfurt HIV Cohort, Germany; Aquitaine Cohort, France; British Columbia Centre for 
Excellence in HIV (BCCfE-HIV), Canada; Royal Free Hospital Cohort, London UK; South Alberta Clinic, Canada; Köln/Bonn 
Cohort, Germany; PISCIS, Catalonia and Balearic islands, Spain; 1917 Clinic Cohort, University of Alabama, Birmingham US; 
University of Washington HIV Cohort, Seattle, US; Veterans Aging Cohort Study (VACS), Connecticut, US
Contributions
M Egger conceived the ART Cohort Collaboration and wrote the original proposal with B Ledergerber, J Lundgren, J Sterne, and A 
Phillips. RJ Harris, J Sterne and M May did statistical analyses. RJ Harris, J Sterne and M Egger wrote the first draft of the paper. A 
Phillips, C Sabin, J Lundgren, A Justice, M May and M Egger contributed to discussions on statistical analyses. All authors 
contributed to writing the paper.
Conflict of interest disclosure
None declared
HHS Public Access
Author manuscript
Antivir Ther. Author manuscript; available in PMC 2015 July 20.
Published in final edited form as:
Antivir Ther. 2008 ; 13(8): 959–967.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Abstract
Background—In HIV-1 infected patients starting highly active antiretroviral therapy (HAART), 
the prognostic value of haemoglobin when starting HAART, and of changes in haemoglobin 
levels, are not well defined.
Methods—We combined data from 10 prospective studies of 12,100 previously untreated 
individuals (25% women). A total of 4,222 patients (35%) were anaemic: 131 patients (1.1%) had 
severe (<8.0 g/dl), 1120 (9%) had moderate (males: 8.0 to <11.0 g/dl, females 8.0 to <10.0 g/dl) 
and 2971 (25%) had mild anaemia (males 11.0 to <13.0 g/dl, females 10.0 to <12.0 g/dl). We 
separately analyzed progression to AIDS or death from baseline and six months using Weibull 
models, adjusting for CD4 cell count, age, sex, and other variables.
Results—During 48,420 person-years of follow-up 1,448 patients developed at least one AIDS 
event and 857 patients died. Anaemia at baseline was independently associated with higher 
mortality: the adjusted hazard ratio (95% confidence interval) for mild anaemia was 1.42 (1.17–
1.73), for moderate anaemia 2.56 (2.07–3.18) and for severe anaemia 5.26 (3.55–7.81). 
Corresponding figures for progression to AIDS were 1.60 (1.37–1.86), 2.00 (1.66–2.40) and 2.24 
(1.46–3.42). At 6 months the prevalence of anaemia had declined to 26%. Baseline anaemia 
continued to predict mortality (and to a lesser extent progression to AIDS) in patients with normal 
haemoglobin or mild anaemia at 6 months.
Conclusions—Anaemia at the start of HAART is an important prognostic factor for short and 
long term prognosis, including in patients whose haemoglobin levels improve or normalize during 
the first 6 months of HAART.
Keywords
HIV/AIDS; highly active antiretroviral therapy (HAART); anaemia; prognosis; mortality
Introduction
The prognosis of HIV-1 infected patients has been dramatically improved by highly active 
antiretroviral therapy (HAART), which typically consists of a combination of three drugs 
[1–4]. Based on data combined from HIV cohort studies in Europe and North America, the 
Antiretroviral Therapy (ART) Cohort Collaboration developed a prognostic model [5;6] that 
is widely used to estimate the risk of AIDS and death in treatment-naïve patients starting 
HAART. A low CD4 T lymphocyte cell (CD4 cell) count at the time of starting HAART 
was most strongly associated with progression to AIDS and death, and a previous AIDS-
defining event, high viral load, transmission via injection drug use and older age are also 
associated with worse prognosis [5].
Several studies from North America and Europe [7–13] have shown that anaemia in HIV-
infected patients is associated with higher rates of disease progression and death, 
independently of the CD4 cell count and other prognostic factors. These studies were mainly 
based on data from the pre-HAART era, or included patients who had been exposed to 
myelosuppressive antiretroviral drugs, particularly zidovudine, before starting HAART. The 
Anaemia in HIV Working Group recently reviewed the literature and concluded that more 
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research was needed on the long-term consequences and prognostic importance of anaemia 
as well as the impact of HAART [14].
We examined the value of anaemia as a prognostic marker in antiretroviral-naïve HIV-
infected patients starting HAART, compared to other prognostic factors, and the prognostic 
importance of the haematological response to HAART using data from the ART Cohort 
Collaboration.
Patients and methods
The ART Cohort Collaboration
The Antiretroviral Therapy Cohort Collaboration (ART-CC, www.art-cohort-
collaboration.org) has been described in detail elsewhere [5;15]. Prospective cohort studies 
were eligible to participate in the collaboration if they had enrolled at least 100 HIV-1 
infected patients aged ≥16 years who had not previously received antiretroviral treatment 
and who had started antiretroviral therapy with a combination of at least three drugs, 
including nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), 
and/or non-nucleoside reverse transcriptase inhibitors (NNRTIs). Patients with HIV-1 RNA 
<1000 copies/ml at initiation of therapy were excluded since they might not have been 
treatment naïve. All cohorts provided anonymized data on a predefined set of demographic, 
laboratory and clinical variables, which were then pooled and analyzed centrally. Data 
included prognostic factors at the time of starting HAART (baseline measurements) and, 
where available, the values of CD4 cell count, HIV-1 RNA and haemoglobin that were 
measured at the nearest time-point to six months (within a window from 3 to 9 months) after 
starting HAART (6-month measurements).
Cohorts included in present analysis
The ART-CC dataset analyzed here includes data up to 2004, with the earliest date of 
starting HAART ranging from May 3, 1995 to March 12, 1997, and the last recorded clinic 
visit ranging from March 28, 2002 to August 11, 2003. Data are from clinical cohorts with 
follow-up during routine care, and visit schedules typically ranging from 3–6 months. Of 12 
cohorts that contributed data, one did not supply haemoglobin measurements, while in 
another cohort haemoglobin values were not regularly recorded. Data from these two 
cohorts were omitted from all analyses. For one cohort, haemoglobin was only recorded 
regularly for a subset of patients from certain clinics; therefore only that part of the data was 
used. The analyses presented here are based on data from the following 10 cohorts: the 
AIDS Therapy Evaluation project, Netherlands (ATHENA), [16] the ANRS Co3 Aquitaine 
Cohort, [17] the British Columbia Centre for Excellence in HIV, [2] Collaborations in HIV 
Outcomes Research (CHORUS), [18] the French Hospital Database on HIV (FHDH), [19] 
the Italian Cohort of Antiretroviral-naïve patients (ICONA), [20] the Cologne/Bonn Cohort, 
[21] the Royal Free Hospital Cohort, [22] the South Alberta Clinic [23] and the Swiss HIV 
Cohort Study (SHCS) [1].
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Definitions of anaemia and outcomes
We used a modified World Health Organisation (WHO) definition of anaemia [24], which 
included an intermediate category for moderate anaemia in order to examine the dose-
response relationship in more detail. Definitions for females were severe anaemia <8.0 g/dl, 
moderate anaemia 8.0 to <10.0 g/dl, mild anaemia 10.0 to <12.0 g/dl, and for males severe 
<8 g/dl, moderate 8.0 to <11.0 g/dl, mild 11.0 to <13.0 g/dl. We considered progression to 
AIDS (based on the clinical part of the 1993 US Centers for Disease Control and Prevention 
revision of the AIDS case definition) [25] as well as progression to death from all causes.
Statistical methods
We used linear regression to examine the effect of initial HAART regimen on 6-month 
haemoglobin levels, adjusting for baseline haemoglobin, age, sex, disease stage and 
presumed transmission via injection drug use (IDU). We compared zidovudine (AZT) 
containing regimens with other regimens and examined whether there were differences 
between AZT combined with lamivudine (3TC) and AZT combined with didanosine (DDI).
We used Weibull proportional hazards models, stratified by cohort, to estimate hazard ratios 
for the effect of prognostic factors. The following were candidate prognostic variables: 
anaemia (categorized as described), CD4 cell count (categorized as <50, 50–99, 100–199, 
200–350 and > 350 cells/μl), HIV-1 plasma RNA (categorized as < 4, 4–5 and >5 log10 
copies/ml), sex, age (<50 or >=50 years), CDC disease stage, presumed transmission groups 
(injection drug use or other) and HAART regimen including AZT. Interactions between 
anaemia, sex and CD4 count were examined. To assess whether haemoglobin could be 
suitably modelled as a continuous variable, we divided haemoglobin into seven equally 
sized groups (septiles) and fitted one model using these groups as a categorical variable and 
one as a linear variable, modelling the linear relationship with the median in each group. 
Likelihood ratio tests were performed to assess departures from linearity.
We measured time from the start of HAART to the date the endpoints occurred. The same 
censoring strategy was used for all cohorts: for AIDS, follow-up was censored on the date of 
the most recent follow-up visit, for mortality on the date the patient was last known to be 
alive. Patients were deemed lost to follow-up if their last clinic visit was more than one year 
before the date of the last record in that cohort. In the model for prognosis from start of 
treatment, only baseline measurements were included. Models examining prognosis 
following initial response to therapy were based on delayed entry, with follow-up time 
starting six months after starting HAART or the date of the 6 month post-HAART 
measurements, whichever was later. In these models we examined the prognostic value of 
change in anaemia at baseline to 6 months while adjusting for other prognostic variables at 
baseline and 6 months. Anaemia was re-categorized to none, mild and moderate/severe at 
baseline and 6 months to produce 9 possible categories for change in anaemia.
Sensitivity analyses
We repeated analyses of the change in anaemia status from baseline to six months excluding 
patients who did not reach viral load <500 copies/ml by 6 months. We also conducted 
sensitivity analyses using multiple imputation [26] to deal with missing data. We derived 20 
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imputed datasets. Estimates from the imputed datasets were combined based on Rubin’s 
rules [26;27].
In all analyses, we used an “intent-to-continue-treatment” approach and thus ignored 
changes to treatment regimen, including treatment interruptions and terminations. All 
analyses were carried out using Stata version 9.0 (StataCorp, College Station, TX, USA). 
Results are presented as hazard ratios (HR) or medians, with 95% confidence intervals (95% 
CI) or interquartile ranges (IQR).
Results
The combined dataset included data on 16,235 patients, of whom 12,100 (75%) had 
measurements of haemoglobin at the time they started HAART. Patients without baseline 
haemoglobin values were more likely to have had AIDS before starting HAART (26% 
compared with 23%), had higher median CD4 cell counts (239 cells/μl compared with 228 
cells/μl) and were less likely to have presumed mode of transmission via IDU (13% vs. 
19%). Of these 12,100 patients, 3,389 (28%) were lost to follow-up; varying from 5% to 
75% across cohorts.
Table 1 shows the characteristics of 12,100 patients with measurements of haemoglobin at 
baseline. The median age was 36 years, and a quarter of patients were women. Heterosexual 
contact was the most frequent risk factor for HIV transmission. The median baseline CD4 
cell count was 228 cells/μl and 23% of patients had AIDS. The median haemoglobin 
concentration was 13.4 g/dl (men 13.6 g/dl, women 11.9 g/dl). A total of 4,222 (35%) 
patients were anaemic: 2,971 (25%) had mild, 1,120 (9%) had moderate and 131 (1%) had 
severe anaemia. The prevalence of anaemia was higher in women than in men, higher in 
older patients than in younger patients, and higher in patients with AIDS compared to 
patients free of AIDS. The prevalence increased with decreasing CD4 cell counts (see 
webtable 1).
Prognostic value of baseline haemoglobin
During 48,420 person-years of follow-up, 1,448 patients developed at least one AIDS event 
and 857 patients died. In Kaplan-Meier plots there was a strong and graded association of 
baseline anaemia with rates of progression to both AIDS and death (figure 1). A graded 
association with progression to both AIDS and death continued to be observed in 
multivariable analyses adjusted for CD4 cell count, viral load and other prognostic variables 
(table 2). HRs for AIDS were 2.24 (95% CI 1.46 to 3.41) for severe anaemia compared with 
no anaemia and 2.00 (1.66 to 2.40) for moderate anaemia compared with no anaemia. 
Corresponding HRs for death were 5.26 (3.55 to 7.81) and 2.56 (2.07 to 3.18) respectively. 
There was little evidence of interactions of the effects of anaemia with sex or with CD4 cell 
counts (p=0.25 and 0.13 respectively for AIDS, p=0.80 and p=0.95 for death). Results were 
similar in analyses based on 16,235 patients, allowing for missing haemoglobin 
measurements using multiple imputation (data available from the authors). The analysis of 
septiles defined by haemoglobin levels indicated that the relation between haemoglobin 
level and risk of progression to AIDS or death was not linear (p=0.042 in men and p=0.015 
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in women). Plots of hazard ratios (webfigure 1) indicated that the risk increased when mild 
anaemia occurred.
Changes in haemoglobin after starting HAART
A total of 14,959 patients were followed up for longer than 6 months (175 patients died and 
1101 patients had their last follow-up visit in the first 6 months after starting HAART). 
9,096 (61%) of the patients followed for longer than 6 months had complete data on all 
variables measured at baseline and at 6 months. Table 3 shows the distribution of these 
patients across categories of anaemia at baseline and 6 months. The prevalence of any type 
of anaemia declined from 35% to 26% (p<0.0001). The median difference in haemoglobin 
levels between baseline and six months was 0.2 g/dl (interquartile range −0.6 to 1.1 g/dl). It 
was 0.0 g/dl (interquartile range −0.8 to 0.9 g/dl) in patients whose regimen included AZT, 
0.0 g/dl (−0.8 to 0.9 g/dl) in patients on AZT + 3TC and 0.0 g/dl (−0.8 to 0.7 g/dl) in 
patients on AZT + DDI.
Prognostic value of anaemia at baseline and 6 months of HAART
We examined rates of progression to AIDS and death from 6 months, treating patients with 
no anaemia both at baseline and 6 months as the reference group (table 4). In general, 
improvement in anaemia during the first months on HAART was associated with lower 
subsequent rates of AIDS and death compared with patients whose anaemia status does not 
improve. However, patients who started HAART with moderate or severe anaemia at 
baseline continued to experience higher rates of AIDS and death than those with no anaemia 
at baseline. Patients with no anaemia at baseline and moderate/severe anaemia at 6 months 
experienced substantially higher mortality rates (hazard ratio 3.93 compared with patients 
with no anaemia at either time). The risk of AIDS was not elevated in this group (hazard 
ratio 1.00), though the confidence interval for this comparison was wide (0.43 to 2.33). 
Sensitivity analyses based on 6,456 patients who suppressed HIV-1 viral replication to <500 
copies/ml at 6 months showed stronger associations (webtable 2). Finally, hazard ratios were 
somewhat higher in analyses based on 14,959 patients, allowing for missing haemoglobin 
measurements using multiple imputation (data available from the authors).
Discussion
In this large collaborative study, we found that about a third of HIV-1 infected patients who 
started HAART in European or North American settings were anaemic. Our results show 
that there is a strong and graded association of the severity of anaemia with rates of 
progression to AIDS and death, both at the time of starting HAART and after the first six 
months of therapy. This association was independent of other prognostic factors, including 
CD4 cell count, an AIDS diagnosis before starting HAART and transmission risk group. An 
increased risk of progression continued to be observed in patients who were anaemic at 
baseline but reached normal or near-normal haemoglobin concentrations within the first six 
months of HAART.
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Strengths and weaknesses
The database of the ART Cohort Collaboration includes patients who were treated in many 
different clinics in Europe and North America. The range of patients was broad: men and 
women, from teenagers to elderly people were included, and the major exposure categories 
were well represented. Our findings should therefore be generalisable across different 
settings and patient groups in industrialized countries. The large number of patients 
included, and consequently large numbers of AIDS events and deaths, meant that we were 
able to estimate associations with precision, and examine the nature of the relationship 
between haemoglobin concentrations and outcomes in detail.
All patients were treatment naïve: baseline haemoglobin levels were therefore not affected 
by antiretroviral drugs. Our analyses did not, however, take other drugs into account that 
cause anaemia in HIV-infected patients, for example antiviral agents such as ganciclovir, 
antifungal agents or drugs used in the chemotherapy of malignancies [14;28]. In patients co-
infected with Hepatitis C virus, treatment with ribavirine and interferon is associated with 
anaemia [29]. At present, the collaborative database does not include information on drugs 
other than antiretroviral treatments, or on HCV co-infection. Another limitation is the 
absence of information on ethnicity: several studies found a higher prevalence of anaemia in 
HIV-1 patients of African American ethnicity than in other races [13;30;31].
Results in context with other studies
In accordance with a recent systematic review of the literature [32], the prevalence of 
anaemia in our study population varied, depending on sex, age and clinical stage. Direct 
comparisons with other studies are difficult, because of differences in study populations, 
presentation of data and definitions used for anaemia. We used the definition that was 
proposed by a WHO expert committee nearly 40 years ago [24]. Based on NHANES III (the 
third US National Health and Nutrition Examination Survey) and the Scripps-Kaiser 
database, these limits should be corrected upwards for white populations in the USA: to 13.7 
g/dl in men aged 20 to 59 years and to 12.2 g/dl in women of the same age group [33]. 
However, our study included many individuals from populations known to have lower 
average haemoglobin concentrations [33], including many patients form Southern Europe, 
as well as African American and African patients.
Our results confirm the association of anaemia with poorer outcomes that was observed in 
previous studies in North America and Europe [7–13]. These studies were based on data 
from the pre-HAART era, or on patients who had been exposed to antiretroviral 
monotherapy or dual therapy, and in particular zidovudine, before starting HAART. Of note, 
in many of these studies results were expressed as the increase in the risk of death per 1 g/dl 
reduction in haemoglobin, with estimates ranging from a 14% to a 57% increase in risk [28]. 
We found that the relation between disease progression and levels of haemoglobin is not 
linear, and this variation in risk estimates may thus to some extent reflect differences in 
distributions of haemoglobin levels across studies.
The increased risk of anaemia associated with zidovudine has been well documented in the 
pre-HAART era [34;35]. Our results indicate that the detrimental effect of zidovudine on 
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haemoglobin levels may be more modest in the context of HAART: the difference in 
haemoglobin levels at six months was 0.2 g/dl. A recent analysis from the Swiss HIV Cohort 
Study showed that patients on zidovudine-containing HAART had haemoglobin levels that 
were 0.5 to 0.8 g/dl lower than in patients not receiving zidovudine up to four years after 
starting HAART [36]. A retrospective chart review at Toronto Hospital indicated that the 
combination of AZT with 3TC may increase the risk of anaemia [37], but this was not 
observed in the present study.
Mechanisms
Anaemia in HIV-infected patients is related to anaemia of chronic disease, infection of 
auxiliary cells in the bone marrow with HIV and other bone marrow infections, neoplasms 
infiltrating the bone marrow, malabsorbtion and myelosuppressive drugs [14;28;38]. The 
Adult and Adolescent Spectrum of HIV Disease Surveillance Project found that 22% of 
anaemia diagnoses recorded 1990 to 1996 were drug-related [8]. In patients successfully 
treated with HAART, the suppression of HIV replication and decline in opportunistic 
infections and neoplasms probably means that antiretroviral drugs will become a relatively 
more important contributor to anaemia [28].
In resource-constrained settings, where 90% of people with HIV/AIDS live, anaemia related 
to causes other than antiretroviral drugs will continue to dominate in the coming years. A 
study in Malawi found that most patients admitted to hospital with severe anaemia had HIV 
infection, but two thirds also had another treatable condition likely to contribute to anaemia, 
most commonly tuberculosis or bloodstream infections [39]. Although HAART is effective 
in these settings [40] and access has improved in recent years, only a minority of patients in 
urgent need of antiretroviral treatment receive it at present [41].
The causal pathways linking anaemia with poor outcomes are not fully understood. It seems 
unlikely that anaemia directly leads to HIV associated disease progression. Rather, anaemia 
may be a proxy measure for more advanced illness. The association with worse prognosis 
that is observed for other chronic diseases, for example cancer [42], supports this notion. 
Interestingly, a recent analysis of the Royal Free cohort found that low serum albumin levels 
predict disease progression and death, independently of haemoglobin concentration [43].
Implications and conclusions
Accurate information on prognosis is of obvious importance to patients and their carers. It is 
also required to inform decisions on when to start HAART: such decisions should be based 
on estimates of progression with and without therapy that take several prognostic factors 
into account, and should not be based only on the CD4 cell count. We will revise the ART 
Cohort Collaboration’s prognostic model to include haemoglobin and thus hope to provide 
more accurate estimates in the future. We emphasize that neither the present study or an 
improved prognostic model can determine the optimum time for starting therapy. Specific 
studies are needed to answer this question. Further research is also required to elucidate the 
mechanisms underlying the prognostic importance of anaemia. Finally, research is needed to 
clarify the place of interventions specifically aimed at correcting anaemia in HIV-1 infected 
patients, including the role of epoietin alfa [44].
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Figure 1. 
Kaplan Meier estimates of the cumulative probability of AIDS (left panels) and death (right 
panels) according to anaemia at baseline (upper panels) or anaemia at 6 months (lower 
panels).
See table 1 for definitions of mild, moderate and severe anaemia.
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Webfigure 1. 
Hazard ratios for progression to AIDS or death by septiles of haemoglobin levels.
Median (range) haemoglobin levels in men were: septile 1: 10.6 g/dl (4.1 to 11.6 g/dl); 
septile 2: 12.3 g/dl (11.7 to 12.8 g/dl); septile 3: 13.2 g/dl (12.9 to 13.5 g/dl); septile 4: 13.9 
g/dl (13.6 to 14.1 g/dl); septile 5: 14.4 g/dl (14.2 to 14.7 g/dl); septile 6: 15.0 g/dl (14.7 to 
15.3 g/dl); septile 7: 15.9 g/dl (15.4 to 22.6 g/dl).
Median (range) haemoglobin levels in women were: septile 1: 9.2 g/dl (2.1 to 10.0 g/dl); 
septile 2: 10.6 g/dl (10.1 to 11.0 g/dl); septile 3: 11.5 g/dl (11.1 to 11.8 g/dl); septile 4: 12.1 
g/dl (11.8 to 12.4 g/dl); septile 5: 12.7 g/dl (12.4 to 12.9 g/dl); septile 6: 13.2 g/dl (13.0 to 
13.6 g/dl); septile 7: 14.2 g/dl (13.7 to 18.0 g/dl).
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Table 1
Baseline characteristics of 12,100 patients with haemoglobin measurements at the time of starting HAART.
Age (years) Median (IQR) 36 (31 to 42)
>50 1,219 (10%)
Sex Female 3,138 (25%)
Presumed mode of transmission Male homosexual contact 4,263 (35%)
Heterosexual contact 4,581 (38%)
Injection-drug use 2,262 (19%)
Other or unknown 994 (8%)
Clinical AIDS 2,737 (23%)
CD4 count (cells/μl) Median (IQR) 228 (93–372)
> 350 3,422 (28%)
200–349 3,236 (27%)
100–199 2,244 (19%)
50–99 1,213 (10%)
<50 1,965 (16%)
Plasma HIV-1 RNA (log10 copies/ml) Median (IQR) 4.9 (4.4–5.4)
< 4 1,423 (12%)
4 – 5 5,168 (43%)
> 5 5,509 (46%)
Haemoglobin (g/dl) Median (IQR) 13.4 (11.9 to 14.6)
Anaemia* Mild 2,971 (25%)
Moderate 1,120 (9%)
Severe 131 (1%)
Initial HAART regimen NNRTI-based 3,087 (26%)
PI-based 8,108 (67%)
Year of initiation of HAART 1995–6 584 (5%)
1997 2,659 (22%)
1998 2,681 (22%)
1999 1,994 (16%)
2000 1,775 (15%)
2001 1,290 (11%)
2002–3 1,117 (9%)
Duration of follow-up (years) Median (IQR) 2.9 (1.41 to 4.43)
< 2 4,066 (34%)
2–4 6,068 (50%)
>5 1,966 (16%)
IQR, interquartile range
*
Mild – males: 11.0 to <13.0 g/dl, females: 10.0 to <12 g/dl; moderate – males: 8.0 to <11.0 g/dl, females: 8.0 to <10.0 g/dl; severe – males and 
females: < 8.0 g/dl.
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Table 2
Hazard ratios for AIDS and death for anaemia and other prognostic factors measured at initiation of HAART.
Adjusted Unadjusted
AIDS Death AIDS Death
Anaemia
 None 1 1 1 1
 Mild 1.60 (1.37–1.86) 1.42 (1.17–1.73) 2.81 (2.45, 3.23) 2.09 (1.74, 2.51)
 Moderate 2.00 (1.66–2.40) 2.56 (2.07–3.18) 5.28 (4.46, 6.24) 5.08 (4.19, 6.15)
 Severe 2.24 (1.46–3.42) 5.26 (3.55–7.81) 6.10 (4.04, 9.21) 10.22 (7.03, 14.84)
CD4 count (cells/μl)
 >350 1 1 1 1
 200–349 1.50 (1.16–1.92) 1.40 (1.06–1.85) 1.68 (1.31, 2.16) 1.62 (1.23, 2.13)
 100–199 2.38 (1.86–3.05) 1.71 (1.28–2.27) 3.52 (2.78, 4.47) 2.69 (2.06, 3.53)
 50–99 3.90 (3.01–5.04) 1.94 (1.42–2.65) 7.37 (5.79, 9.37) 3.83 (2.88, 5.09)
 <50 4.87 (3.81–6.24) 2.30 (1.72–3.07) 11.81 (9.51, 14.67) 5.62 (4.40, 7.18)
Plasma viral load (log10 copies/ml)
 3 – 4 1 1 1 1
 4 – 5 1.16 (0.88–1.52) 0.81 (0.62–1.07) 1.35 (1.03, 1.78) 0.87 (0.66, 1.14)
 > 5 1.46 (1.12–1.91) 0.81 (0.62–1.07) 3.13 (2.41, 4.06) 1.53 (1.18, 1.98)
Other risk factors
 Female 0.79 (0.68–0.92) 0.77 (0.63–0.93) 0.81 (0.70, 0.94) 0.77 (0.64, 0.93)
 Age > 50 1.12 (0.94–1.35) 1.96 (1.60–2.39) 1.32 (1.10, 1.57) 1.92 (1.59, 2.32)
 CDC stage C 2.92 (2.49–3.41) 2.14 (1.79–2.56) 6.73 (5.85, 7.73) 3.90 (3.35, 4.54)
 Presumed transmission from IDU 1.44 (1.23–1.69) 2.44 (2.05–2.91) 1.40 (1.20, 1.64) 2.09 (1.77, 2.48)
Analysis based on 12,100 individuals with complete data on all variables. *Hazard ratios adjusted for other variables in the table and zidovudine 
(AZT) in initial HAART regimen, stratified by year of starting HAART and cohort
CDC, Centers for Disease Control and Prevention; IDU, injection drug use
See table 1 for definitions of mild, moderate and severe anaemia.
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Table 4
Hazard ratios for AIDS and death for change in anaemia status from baseline to six months after starting 
HAART, adjusting for other factors.
Anaemia status at baseline Anaemia status at 6 months Number of patients AIDS Death
None None 5358 1 (ref) 1 (ref)
Mild None 1194 0.98 (0.74, 1.31) 0.85 (0.61, 1.20)
Moderate/severe None 297 1.37 (0.90, 2.09) 1.52 (0.99, 2.34)
None Mild 723 1.20 (0.82, 1.77) 1.30 (0.88, 1.91)
Mild Mild 857 1.55 (1.17, 2.06) 1.49 (1.08, 2.06)
Moderate/severe Mild 339 1.84 (1.28, 2.65) 1.89 (1.31, 2.73)
None Moderate/severe 61 1.00 (0.43, 2.33) 3.93 (2.18, 7.07)
Mild Moderate/severe 112 2.51 (1.50, 4.19) 3.47 (2.23, 5.40)
Moderate/severe Moderate/severe 155 2.59 (1.60, 4.19) 3.14 (2.06, 4.77)
Analyses based on 9,096 individuals with complete data on all prognostic variables.
Hazard ratios adjusted for CD4 cell count and plasma viral load at baseline and six months, age, sex, CDC stage, AIDS in first six months, 
presumed HIV transmission injection drug use and regimen including zidovudine (AZT) at baseline, stratified by year of starting HAART and 
cohort.
See table 1 for definitions of mild, moderate and severe anaemia.
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Webtable 2
Hazard ratios for AIDS and death for change in anaemia status from baseline to six months after starting 
HAART, adjusting for other factors. Analyses based on 6,456 patients who suppressed HIV-1 viral replication 
to <500 copies/ml at 6 months.
Anaemia status at baseline Anaemia status at 6 months N AIDS Death
None None 3877 1 (ref) 1 (ref)
Mild None 823 0.88 (0.57, 1.37) 1.08 (0.68, 1.70)
Moderate/severe None 203 1.13 (0.61, 2.10) 1.96 (1.08, 3.55)
None Mild 539 1.05 (0.58, 1.90) 1.18 (0.68, 2.05)
Mild Mild 568 2.14 (1.45, 3.16) 1.54 (0.96, 2.46)
Moderate/severe Mild 242 2.39 (1.43, 3.99) 2.27 (1.38, 3.75)
None Moderate/severe 41 0.91 (0.13, 6.57) 8.70 (4.32, 17.50)
Mild Moderate/severe 67 1.35 (0.42, 4.32) 5.99 (3.26, 11.02)
Moderate/severe Moderate/severe 96 1.90 (0.89, 4.04) 3.35 (1.73, 6.46)
Hazard ratios adjusted for CD4 cell count and plasma viral load at baseline and six months, age, sex, CDC stage, AIDS in first six months, 
presumed HIV transmission injection drug use and regimen including zidovudine (AZT) at baseline, stratified by year of starting HAART and 
cohort.
See table 1 for definitions of mild, moderate and severe anaemia.
Antivir Ther. Author manuscript; available in PMC 2015 July 20.
